Aiming to add to its vitiligo arsenal, US biopharma firm Incyte (Nasdaq: INCY) today announced that it has entered into an agreement to acquire Villaris Therapeutics, in a deal that could cost it as much as $1.4 billion.
Villaris is an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. Its lead asset, auremolimab (VM6), is an anti-interleukin (IL)-15Rβ monoclonal antibody (MAb). Founded in 2019, Villaris is based in Cary, North Carolina.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze